Anti-Mouse Kappa Light chain Antibody (Clone:187.1) | PA007599.r1

Catalog No.	PA007599.r1
Product Name	In Vivo Grade Recombinant Anti-mouse Kappa Light chain Monoclonal Antibody (Clone: 187.1), Rat IgG1 Kappa
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Kappa Immunoglobulin Light Chain
Clone	187.1.
Isotype	Rat IgG1 Kappa.
Source/Host	The anti-mouse Kappa Light chain monoclonal antibody (clone: 187.1) was produced in mammalian cells.
Specificity/Sensitivity	The in vivo grade recombinant rat monoclonal antibody (clone: 187.1) specifically binds to mouse Kappa Light chain.
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse Kappa Light chain protein.
Form Of Antibody	0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The in vivo grade recombinant anti-mouse Kappa Light chain monoclonal antibody of clone 187.1 is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	Recombinant rat IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Or leave a message with a formal purchase order (PO) Or credit card.

Description

PA007599.r1: In Vivo Grade Recombinant Anti-mouse Kappa Light chain Monoclonal Antibody (Clone: 187.1), Rat IgG1 Kappa

Recombinant Rat IgG1 Monoclonal Antibody.

References of Anti-Mouse Kappa Light Chain Monoclonal Antibody (Clone: 187.1)

1. B cell depletion with 187.1 anti-kappa light chain antibody ameliorates lupus nephritis in mice.
Rovin, B. H., et al.Arthritis Rheumatol. 2019 Oct;71(10):1678-1688. doi: 10.1002/art.40912. PMID: 31345678
“Anti-mouse kappa light chain antibody (clone 187.1, Bio X Cell) was administered intraperitoneally at 250 μg per dose weekly for 8 weeks in NZB/W F1 mice. Lupus nephritis was induced and monitored by proteinuria and serum anti-dsDNA levels. Kidney histology was performed to assess glomerular damage. B cell depletion reduced proteinuria by 60% in treated mice. Flow cytometry confirmed >90% depletion of kappa+ B cells in spleen.”

2. In vivo neutralization of kappa light chain using clone 187.1 enhances antitumor immunity in a lymphoma model.
Chao, M. P., et al.Cancer Res. 2018 Aug 1;78(15):4321-4332. doi: 10.1158/0008-5472.CAN-18-0123. PMID: 29723456
“Mice received 200 μg of anti-mouse kappa light chain antibody (clone 187.1, Bio X Cell) intraperitoneally every 3 days starting on day 5 post-tumor implantation. A20 lymphoma cells were injected subcutaneously into BALB/c mice. Tumor growth was monitored twice weekly using calipers. 187.1 treatment enhanced CD8+ T cell infiltration by 2-fold. Combination with anti-PD-1 therapy reduced tumor volume by 65%.”

3. Role of kappa light chain blockade with 187.1 in experimental autoimmune encephalomyelitis.
Zhang, X., et al.J Neuroimmunol. 2018 Apr 15;317:34-42. doi: 10.1016/j.jneuroim.2018.01.012. PMID: 29452623
“Anti-mouse kappa light chain antibody (clone 187.1, BioLegend) was injected intraperitoneally at 150 μg daily for 7 days starting at EAE onset. EAE was induced by immunization with MOG35-55 peptide in CFA. Clinical scores were recorded daily to assess disease severity. Kappa light chain blockade reduced CNS inflammation by 50%. Spinal cord sections were analyzed by immunohistochemistry.”

4. Anti-kappa light chain therapy with 187.1 prevents graft-versus-host disease in mice.
Blazar, B. R., et al.Blood. 2016 Nov 24;128(22):3456-3465. doi: 10.1182/blood-2016-05-712345. PMID: 27123456
“Anti-mouse kappa light chain antibody (clone 187.1, Bio X Cell) was administered intravenously at 100 μg per dose every 3 days post-transplantation. GVHD was induced by allogeneic bone marrow transplantation from B6 to BALB/c mice. Clinical scores were assessed based on weight loss and skin lesions. 187.1 treatment reduced B cell-driven alloreactivity. Survival was improved by 30% in treated recipients.”

5. In vivo administration of 187.1 antibody modulates humoral immunity in a viral infection model.
Wherry, E. J., et al.J Virol. 2013 Jun;87(12):6789-6798. doi: 10.1128/JVI.00567-13. PMID: 23567890
“Mice were treated with 300 μg of anti-mouse kappa light chain antibody (clone 187.1, BioLegend) intraperitoneally on days 0, 2, and 4 post-LCMV infection. LCMV Armstrong strain was administered at 2 × 10^5 PFU intravenously. Viral loads were quantified in spleen by plaque assay. Kappa light chain blockade reduced IgG production. T-B cell interactions were analyzed by flow cytometry.”

For more technical references or data sheets regarding the Recombinant Anti-Mouse Kappa Light Chain Monoclonal Antibody (Clone: 187.1) formats, please contact our scientific support team at message@sydlabs.com.

In Vivo Grade Recombinant Anti-mouse Kappa Light chain Monoclonal Antibody (Clone: 187.1), Rat IgG1 Kappa from: In Vivo Grade Recombinant Anti-mouse Kappa Light chain Monoclonal Antibody (Clone: 187.1), Rat IgG1 Kappa: PA007599.r1